Interactome of human and SARS-CoV-2 proteins to identify human hub proteins associated with comorbidities. (November 2021)

• Record Type: Journal Article
• Authors: Ghosh, Nimisha; Saha, Indrajit; Sharma, Nikhil
• Is Part Of: Computers in biology and medicine. Volume 138(2021)
• Publication Date: 2021-11
• Subjects: COVID-19 -- Comorbidities -- Hub proteins -- Protein-protein interaction -- Repurposable drugs -- SARS-CoV-2; Medicine -- Data processing -- Periodicals; Biology -- Data processing -- Periodicals; 610.285
• DOI: 10.1016/j.compbiomed.2021.104889
• Languages: English
• ISSNs: 0010-4825

Abstract

Abstract: SARS-CoV-2 has a higher chance of progression in adults of any age with certain underlying health conditions or comorbidities like cancer, neurological diseases and in certain cases may even lead to death. Like other viruses, SARS-CoV-2 also interacts with host proteins to pave its entry into host cells. Therefore, to understand the behaviour of SARS-CoV-2 and design of effective antiviral drugs, host-virus protein-protein interactions (PPIs) can be very useful. In this regard, we have initially created a human-SARS-CoV-2 PPI database from existing works in the literature which has resulted in 7085 unique PPIs. Subsequently, we have identified at most 10 proteins with highest degrees viz. hub proteins from interacting human proteins for individual virus protein. The identification of these hub proteins is important as they are connected to most of the other human proteins. Consequently, when they get affected, the potential diseases are triggered in the corresponding pathways, thereby leading to comorbidities. Furthermore, the biological significance of the identified hub proteins is shown using KEGG pathway and GO enrichment analysis. KEGG pathway analysis is also essential for identifying the pathways leading to comorbidities. Among others, SARS-CoV-2 proteins viz. NSP2, NSP5, Envelope and ORF10 interacting with human hub proteins like COX4I1, COX5A, COX5B, NDUFS1, CANX, HSP90AA1 and TP53 lead to comorbidities. Such comorbidities are Alzheimer, Parkinson, Huntington, HTLV-1 infection, prostate cancer and viral carcinogenesis. Subsequently, using Enrichr tool possible repurposable drugs which target the human hub proteins are reported in this paper as well. Therefore, this work provides a consolidated study for human-SARS-CoV-2 protein interactions to understand the relationship between comorbidity and hub proteins so that it may pave the way for the development of anti-viral drugs. Highlights: Creation of Human-SARS-CoV-2 PPIs based on literature resulting in 7085 unique PPIs. At most 10 hub proteins are identified from human proteins for each SARS-CoV-2 protein. Analysis of KEGG pathways for comorbidities. Analysis of GO-enrichment pathways to understand the biological significance. Identification of potential repurposable drugs.